Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8589496 | 0.98 | TAAR1 (0.70) | TAAR1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL3436874 | 0.94 | TAAR1 (0.76) | TAAR1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL2615235 | 0.85 | TAAR1 (1.00) | TAAR1L3MBTL1SIGMAR1TMEM97 | |
| SCHEMBL681435 | 0.85 | TAAR1 (1.00) | TAAR1L3MBTL1SIGMAR1TMEM97 | |
| SCHEMBL14178223 | 0.82 | MEN1 (0.74) | TAAR1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL10574057 | 0.82 | TAAR1 (0.62) | TAAR1SCN5A | |
| SCHEMBL30229979 | 0.81 | L3MBTL1 (0.67) | TAAR1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL18551667 | 0.81 | L3MBTL1 (0.67) | TAAR1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL11583176 | 0.80 | TAAR1 (0.61) | TAAR1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL10571903 | 0.79 | TAAR1 (0.59) | TAAR1SCN5ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728237-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| WO-2018112122-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | DREXEL UNIVERSITY (US) | 2018-06-21 | — | — | WO | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | TAAR1 76/4885L3MBTL1 3041/4885SIGMAR1 269/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | TAAR1 76/4885L3MBTL1 3041/4885SIGMAR1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.